KOROSTATIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KOROSTATIN (KOROSTATIN).
KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.
| Metabolism | Metabolized via hydrolysis to an inactive metabolite; minimal hepatic cytochrome P450 involvement. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other |
| Half-life | 8-12 hours in normal renal function; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | 99% bound to albumin |
| Volume of Distribution | 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid |
| Bioavailability | Oral: 70-80% |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours |
| Molecular Weight | 452.6 |
50 mg orally twice daily
| Dosage form | TABLET |
| Renal impairment | GFR ≥60 mL/min: No adjustment. GFR 30-59 mL/min: 25 mg twice daily. GFR 15-29 mL/min: 25 mg once daily. GFR <15 mL/min: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 25 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Weight ≥20 kg: 1.25 mg/kg twice daily; maximum 50 mg twice daily. Weight <20 kg: Not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and consider age-related decline in GFR. |
| 1st trimester | Insufficient human data; animal studies show teratogenicity at high doses. Avoid unless benefit outweighs risk. |
| 2nd trimester | Use only if clearly needed; potential fetal toxicity reported in animal studies. |
| 3rd trimester | Avoid in third trimester; possible neonatal toxicity (e.g., hypotension, renal impairment). |
Clinical note
Comprehensive clinical and safety monograph for KOROSTATIN (KOROSTATIN).
| Placental transfer | Crosses placenta in animal studies; human data limited, but expected to transfer due to molecular weight < 500 Da. |
| Breastfeeding | Excreted in breast milk in low amounts; limited data in humans. Consider risk of infant exposure vs. benefit of breastfeeding. Monitor infant for diarrhea, rash, or appetite changes. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to korostatin or any excipientSevere hepatic impairmentConcomitant use with strong CYP3A4 inhibitors
| Precautions | Increased risk of bleeding, especially in patients with renal impairment, concomitant use of antiplatelet agents or anticoagulants, and in elderly patients., Spinal/epidural hematomas may occur with neuraxial anesthesia or spinal puncture, leading to long-term or permanent paralysis., Discontinue KOROSTATIN prior to invasive procedures; monitor for signs of bleeding., Hepatic toxicity: monitor liver enzymes; discontinue if significant elevation occurs. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing KOROSTATIN levels. Avoid high-fat meals within 2 hours of dosing as they may reduce absorption. Maintain adequate hydration to prevent constipation. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: No human data; animal studies show skeletal malformations at 5x MRHD. Second/third trimester: Risk of fetal renal impairment and oligohydramnios, especially with prolonged use. |
| Fetal Monitoring | Monitor fetal renal function via ultrasound (amniotic fluid index) and Doppler. Evaluate maternal renal function (serum creatinine, BUN) and blood pressure. |
| Fertility Effects | Reversible reduction in spermatogenesis in males; ovarian suppression in females with return to baseline after discontinuation. |
| Clinical Pearls | KOROSTATIN is a selective inhibitor of the KOR receptor, primarily used for treatment of major depressive disorder with anhedonia. Monitor for QTc prolongation; baseline and periodic ECGs are recommended. Avoid abrupt discontinuation due to risk of withdrawal syndrome including insomnia, anxiety, and muscle aches. Titrate dose slowly to minimize side effects like dizziness and somnolence. Use with caution in patients with hepatic impairment; dose adjustment required for Child-Pugh B or C. |
| Patient Advice | Take exactly as prescribed; do not change dose without consulting your doctor. · May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you. · Report any irregular heartbeat or fainting spells immediately. · Do not stop taking suddenly; your doctor will guide you on tapering to avoid withdrawal. · Avoid alcohol while taking this medication. · Tell your doctor about all other medications, especially those affecting heart rhythm (e.g., certain antibiotics, antifungals). |